LTR PharmaASX:LTP -4.27%15 FCF Yield % is -6.83 as of Jun. 26, 2026. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, LTR Pharma ranks better than 58.18% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
LTR Pharma FCF Yield % Related Terms
LTR Pharma FCF Yield % Historical Data
* Premium members only.
The historical data trend for LTR Pharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, LTR Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where LTR Pharma's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a FCF Yield % of -6.83 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #593 out of 1418 companies in the Biotechnology industry, placing it in the top 41.8%.
Is LTR Pharma's FCF Yield % too high?
LTR Pharma's current FCF Yield % is -6.83. Based on the distribution chart, LTR Pharma ranks #593 out of 1418 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #593 out of 1418 companies for FCF Yield %. This puts LTR Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on LTR Pharma and its competitors. LTR Pharma's current FCF Yield % is -6.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current FCF Yield % of -6.83. The current FCF Yield % is -6.83. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current FCF Yield % is -6.83 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 